BladderChek Test
This article was originally published in The Tan Sheet
Executive Summary
Diagnostic products developers Matritech and Inverness Medical Innovations have signed a manufacturing and distribution agreement to collaborate and seek FDA approval for OTC sale of the NMP22 BladderChek Test, the companies announce Nov. 6. The product, developed by Matritech, is the only FDA approved physician-office test for both the diagnosis and monitoring of bladder cancer, the companies say. The firms will assess market opportunity under their agreement and "anticipate the OTC distribution would be introduced in the U.S. as soon as FDA approval is received." Home diagnostic products already marketed by Inverness include the Clearblue and Fact Plus home pregnancy tests...